• No results found

University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Evaluation of renal end points in nephrology trials

Weldegiorgis, Misghina Tekeste

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Weldegiorgis, M. T. (2017). Evaluation of renal end points in nephrology trials. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

___________________________________________________________________________

(3)

123

122

Acknowledgments

___________________________________________________________________________

Acknowledgments

Thanks to God for granting me the wisdom, health, and strength to undertake this research task and enabling me to its completion.

I am deeply indebted to my promotors, Prof. Dick de Zeeuw and Prof. Hiddo Lambers Heerspink, for their excellent guidance, expertise, and encouragement during my Ph.D. project. I have been fortunate to have promotors who cared so much about my work, and who gave me valuable feedback so promptly. I thank you so much for the knowledge you have passed on, and I will always be thankful for having the opportunity to be supervised by you. I also would like to extend my gratitude to the many co-authors, for their collaboration, expertise, and input.

To the reading committee assessing this thesis, Prof. R.T. Gansevoort, Prof. S.J.L. Bakker, and Prof. H.G.M. Leufkens, your efforts are highly appreciated.

I would like to express my deepest appreciation to my mother, Minya, for her constant love and support. Remembering her always give me energy. I sincerely miss my father, Tekeste who is not with me to share this joy. I am very much indebted to my siblings, Abeba, Yonas, Yordanos, and Selamawit for their encouragement and emotional support.

Special mention goes to my paranymphs, Sieta de Vries and Kirsten Smits, for your assistance in translating the summary part of my thesis from English to Dutch. I would like to extend thanks to all my colleagues in the Department of Pharmacy and Pharmacology for the friendly and cooperative atmosphere at work and also useful feedback and insightful comments on my work.

Completing this work would have been all difficult were it not for the support provided by all my friends within and outside the Netherlands. I am indebted to them for their help, care, and hospitality.

Acknowledgments

The work conducted in this thesis has been possible by financial support from the research institute, Groningen University Institute for Drug Exploration (GUIDE), UMCG, to which I would like to express my gratitude.

I am deeply indebted to my promotors, Prof. Dick de Zeeuw and Prof. Hiddo Lambers Heerspink, for their excellent guidance, expertise, and encouragement during my Ph.D. project. I have been fortunate to have promotors who cared so much about my work, and who gave me valuable feedback so promptly. I thank you so much for the knowledge you have passed on, and I will always be thankful for having the opportunity to be supervised by you. Hiddo assisted financially for my thesis cover. I am grateful in every possible way.

I would like to acknowledge the co-authors listed in the different chapters, for their collaboration, expertise, and input. Liang Li, Hans-Henrik Parving, Fan Fan Hou, Giuseppe Remuzzi, Tom Greene, Lesley Inker, Ron Gansevoort, Jamie P Dwyer, Hasi Mondal, Josef Coresh, Andrew S. Levey, and Peter Mol, thank you for your contributions to this thesis.

To the reading committee assessing this thesis, Prof. R.T. Gansevoort, Prof. S.J.L. Bakker, and Prof. H.G.M. Leufkens, your efforts are highly appreciated.

I would like to thank my colleagues in the Department of Pharmacy and Pharmacology for the friendly and cooperative atmosphere at work and also useful feedback and insightful comments on my work during the Monday morning meetings and Thursday meetings (gangoverleg). I would like to extend thanks to colleagues from the Departments of Nephrology and Epidemiology. Prof. Flora Haaijer-Ruskamp, Prof. Petra Denig, and dr. Peter Mol, thank you for your guidance and feedback during our weekly

gangoverleg meetings. Special thanks to Paul Smink, for your help with R-syntax during

the beginning of my Ph.D. project. Special mention goes to my paranymphs, Sieta de Vries and Kirsten Smits, for your friendship as well as assistance in translating the summary part of my thesis from English to Dutch. Thank you for being my paranymph. Alexandra, Ardy, and Marja thank you for your help with all the administration issues. Wessel, thank you for your help with my computer and networks issues.

(4)

A

123

122

Acknowledgments

___________________________________________________________________________

Completing this work would have been all difficult were it not for the support provided by all my relatives and friends within and outside the Netherlands. Thank you for the help, care, and hospitality. Thank you to the Eritrean community in Utrecht and Groningen, Ethiopian community in Groningen, and African Students Community Groningen for making my stay in the Netherlands full of fun and joy.

Last but not least I would like to express my deepest gratitude to my mother, Minya, for her constant love and support. Remembering her always give me energy. I sincerely miss my father, Tekeste who is not with me to share this joy. I am very much indebted to my siblings, Abeba, Yonas, Yordanos, and Selamawit for their encouragement and emotional support.

Finally, I would like to thank God for granting me the wisdom, health, and strength to undertake this research task and enabling me to its completion.

(5)

___________________________________________________________________________

(6)

___________________________________________________________________________

Acknowledgments

Curriculum Vitae

Misghina T. Weldegiorgis was born in mid-eighties in Ethiopia to Eritrean parents. After that, he lived in Asmara, Eritrea with his mother and siblings. He spent his childhood in a multilingual and multicultural environment.

Misghina obtained BSc degree in Pharmacy from the University of Asmara in 2008 and received MSc degree in epidemiology with specialization in pharmacoepidemiology from Utrecht University in 2014.

He had obtained a wide-range of expertise as a hospital pharmacist, pharmaceutical information officer, and drug registration and evaluation officer in Eritrea, before starting his Ph.D.

Misghina has tremendous passion and interest in the design and analysis of large-scale randomized clinical trials and observational studies in nephrology. In 2012, he started his Ph.D. research entitled “evaluation of renal end points in nephrology trials” under the supervision of prof. dr. Dick de Zeeuw and prof. dr. Hiddo Lambers Heerspink at the University Medical Center Groningen. In February 2017, Misghina started working as an epidemiologist at the George Institute for Global Health at the University of Oxford.

(7)

126

Curriculum Vitae

Misghina T. Weldegiorgis was born in mid-eighties in Ethiopia to Eritrean parents. After that, he lived in Asmara, Eritrea with his mother and siblings. He spent his childhood in a multilingual and multicultural environment.

Misghina obtained BSc degree in Pharmacy from the University of Asmara in 2008 and received MSc degree in epidemiology with specialization in pharmacoepidemiology from Utrecht University in 2014.

He had obtained a wide-range of expertise as a hospital pharmacist, pharmaceutical information officer, and drug registration and evaluation officer in Eritrea, before starting his Ph.D.

Misghina has tremendous passion and interest in the design and analysis of large-scale randomized clinical trials and observational studies in nephrology. In 2012, he started his Ph.D. research entitled “evaluation of renal end points in nephrology trials” under the supervision of prof. dr. Dick de Zeeuw and prof. dr. Hiddo Lambers Heerspink at the University Medical Center Groningen. In February 2017, Misghina started working as an epidemiologist at the George Institute for Global Health at the University of Oxford.

Acknowledgments

(8)
(9)

Evaluation of renal

end points in nephrology trials

Misghina T. Weldegiorgis

E va l u a T ion of r E nal E nd poin T s in n E phrol og y T rials | Mis ghina T . W E ld E giorgis

Invitation

You are cordially invited to attend the public defence of the doctoral thesis entitled

Evaluation

of renal end points

in nephrology trials

by Misghina T. Weldegiorgis On Wednesday 8 November 2017 at 16.15 hours in the Academiegebouw, Broerstraat 5, Groningen Reception immediately following in the Spiegelzaal

of the Academiegebouw Misghina T. Weldegiorgis

110 Rose Hill, OX4 4HX Oxford, England misgu22@gmail.com Paranymphs: Kirsten Smits k.p.j.smits@umcg.nl Sieta de Vries s.t.de.vries@umcg.nl

Referenties

GERELATEERDE DOCUMENTEN

The current established trial end points in CKD are a mixture of a filtration based end point (doubling of serum creatinine or eGFR slope) and overall function of kidney

In the pooled dataset, a multivariable linear regression showed that higher baseline eGFR, male gender, diabetes status, steeper eGFR slope,

In addition, as we showed in this study, if the beneficial effect of the intervention is greater in patients with a faster rate of eGFR decline, the time to overcome an

Background: A doubling of serum creatinine value, corresponding to a 57% decline in estimated glomerular filtration rate (eGFR), is used frequently as a component of a composite

We therefore compared the time to RRT with the time to a fixed estimated glomerular filtration rate (eGFR) threshold and assessed the effect of the renoprotective drug irbesartan

to show that these effects may have clinical impact as the effect of the ARB irbesartan is smaller on the RRT end point compared to an end point purely based on the filtration

Vervolgens bleven we aantonen dat deze effecten klinische impact kunnen hebben omdat het effect van de ARB irbesartan kleiner lijkt te zijn op het eindpunt van

The current established trial end points in CKD are a mixture of a filtration based end point (doubling of serum creatinine or eGFR slope) and overall function of kidney